Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017 Summary Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2017, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection and Liver Transplant Rejection. Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects - The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview 6 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 12 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 14 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 18 Astellas Pharma Inc 18 Hookipa Biotech AG 18 Immunomic Therapeutics Inc 18 Vakzine Projekt Management GmbH 19 Vaximm AG 19 VBI Vaccines Inc 20 Vical Inc 20 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 21 ASP-0113 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CyMVectin - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 HB-101 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 PepVax - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Triplex - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VBI-1901 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 VPM-2001 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 VXM-65 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products 38 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 39 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones 40 Featured News & Press Releases 40 Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 40 Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 40 May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 41 Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 41 Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections 42 Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 42 Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood 43 Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 44 Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 44 Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 45 Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 45 Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine 46 Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 46 Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 47 Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 9 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products under Investigation by Universities/Institutes, H2 2017 12 Products under Investigation by Universities/Institutes, H2 2017 13 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 17 Pipeline by Astellas Pharma Inc, H2 2017 18 Pipeline by Hookipa Biotech AG, H2 2017 18 Pipeline by Immunomic Therapeutics Inc, H2 2017 19 Pipeline by Vakzine Projekt Management GmbH, H2 2017 19 Pipeline by Vaximm AG, H2 2017 19 Pipeline by VBI Vaccines Inc, H2 2017 20 Pipeline by Vical Inc, H2 2017 20 Dormant Projects, H2 2017 38 Discontinued Products, H2 2017 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
